These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31606603)

  • 1. Skin warts during fingolimod treatment in patients with multiple sclerosis.
    Jaafar N; Zeineddine M; Massouh J; Yamout BI
    Mult Scler Relat Disord; 2019 Nov; 36():101437. PubMed ID: 31606603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warts and all: Fingolimod and unusual HPV-associated lesions.
    Triplett J; Kermode AG; Corbett A; Reddel SW
    Mult Scler; 2019 Oct; 25(11):1547-1550. PubMed ID: 30427266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
    Mhanna E; Nouchi A; Louapre C; De Paz R; Heinzlef O; Bodini B; Assouad R; Chochon F; Lubetzki C; Papeix C; Pourcher V; Maillart E
    Mult Scler; 2021 Oct; 27(11):1794-1798. PubMed ID: 33629615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
    Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
    Ann Neurol; 2020 May; 87(5):688-699. PubMed ID: 32056253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
    Takahashi K
    J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
    Macaron G; Ontaneda D
    Mult Scler; 2019 Oct; 25(11):1550-1552. PubMed ID: 30427261
    [No Abstract]   [Full Text] [Related]  

  • 10. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.
    Fragoso YD; Gama PDD; Gomes S; Khouri JMN; Matta APDC; Fernanda Mendes M; Stella CRAV
    Mult Scler Relat Disord; 2016 Mar; 6():64-65. PubMed ID: 27063625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?
    Nakahara J; Tomaske L; Kume K; Takata T; Kamada M; Deguchi K; Kufukihara K; Schneider R; Gold R; Ayzenberg I
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e559. PubMed ID: 31044147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.
    Grebenciucova E; Reder AT; Bernard JT
    Mult Scler Relat Disord; 2016 Sep; 9():158-62. PubMed ID: 27645366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.
    Zhao Z; Ma CL; Gu ZC; Dong Y; Lv Y; Zhong MK
    Front Immunol; 2021; 12():611711. PubMed ID: 33763062
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis.
    Kal A; Oğuz Ulusoy M; Horasanlı B; Cezairlioğlu Ş; Kal Ö
    Mult Scler Relat Disord; 2017 May; 14():4-7. PubMed ID: 28619430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod.
    Benedetti MD; Marangi A; Bozzetti S; Gobbin F; Turatti M; Pea M; Gajofatto A; Mocella S
    Mult Scler Relat Disord; 2018 Jul; 23():24-26. PubMed ID: 29734135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
    Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.